- Policy
- 1st bispecific antibody Epkinly approved with a condition
- by Lee, Hye-Kyung Jul 9, 2024 05:51am
- 'Epkinly (epcoritamab),' the first T-cell&8211;engaging bispecific&160;antibody, was found to have been approved under the condition that the company submits Phase III trial data. In Korea, the approval was granted on March 20 based on Phase II clinical trial data and a Phase III trial protocol, but at the time, a condition was added th
- Company
- Takeda seeks top-line growth to KRW 300 billion
- by Hwang, Byung-woo Jul 9, 2024 05:51am
- Takeda Pharmaceuticals Korea achieved a double win last year, seeing improvements in sales and operating income. In particular, thanks to the growth of its anti-cancer drug portfolio, the company's sales exceeded the KRW 250 billion mark for the first time in 3 years since 2020, increasing sales growth for the second consecutive year. i
- Policy
- BMS’ Camzyos and Handok’s Empaveli pass the DREC review
- by Lee, Tak-Sun Jul 9, 2024 05:51am
- Bristol Myers Squibb Korea’s 'Camzyos Cap,' a treatment for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), has passed the Drug Reimbursement Evaluation Committee (DREC) review after reconsideration. Handok’s 'Empaveli Inj,' a treatment for paroxysmal nocturnal hemoglobinuria (PNH), also obtained approval for reimbursement and m
- Policy
- Reassessing the comparison of foreign drug pricing is 'idle'
- by Lee, Tak-Sun Jul 8, 2024 05:46am
- The 10th public-private meeting has been held to reassess the comparative methods of foreign drug pricing. However, they exchanged different opinions without reaching a concrete decision. Pharmaceutical industry has particularly opposed to the use of drug pricing references from Germany and Canada. It remains to be seen how the two part
- Company
- HCV testing added to the National Health Screening Program
- by Hwang, Byung-woo Jul 8, 2024 05:46am
- The government's decision to introduce the long-discussed hepatitis C antibody testing to the national screening program is expected to have a positive impact on its treatment market. According to industry sources, the decision is encouraging as it enables the first step of identifying hepatitis C patients. However, how to link diagnosis and
- Company
- New PNH drugs introduced into AstraZeneca’s reign
- by Son, Hyung-Min Jul 8, 2024 05:45am
- Competition is in full swing in the paroxysmal nocturnal&160;hemoglobinuria (PNH) market, which is currently dominated by AstraZeneca's treatments such as Soliris and Ultomiris, with the introduction of new drugs that have new mechanisms of action soon to emerge in the market. Recently, Handok's Empaveli is nearing reimbursement in Korea, and N
- Company
- K-Bio receives FDA Orphan Drug Designations with novel drugs
- by Son, Hyung-Min Jul 8, 2024 05:45am
- In the first half of the year, Korean biopharmaceutical companies succeeded in obtaining numerous Orphan Drug Designations. Few patients have rare diseases but developing innovative new drugs can create added value and an exclusive position in the market. In the United States, if a drug is designated as an orphan drug, it is provided seven years
- Company
- Roche Korea starts reimb process for Columvi in Korea
- by Eo, Yun-Ho Jul 8, 2024 05:45am
- The reimbursement listing process for ‘Columvi,' the first bispecific antibody treatment option for lymphoma, will begin in Korea. According to Dailypharm coverage, Roche Korea's CD20-CD3 bispecific antibody for diffuse large B-cell lymphoma (DLBCL) Columvi (glofitamab) is expected to be presented to the Health Insurance Review and Asses
- InterView
- “Prolia demonstrated a long-term treatment effect"
- by Son, Hyung-Min Jul 5, 2024 05:49am
- “Prolia has consistently been proven to increase bone density based on clinical trials conducted over 10 years. Patients prescribed with Prolia have demonstrated such. Based on this evidence we hope that Prolia’s preventative effect on bone fracture becomes known in South Korea.“ During a recent meeting with Daily Pharm, David Dempster,
- Company
- "Allowing switching between atopic dermatitis treatments"
- by Hwang, Byung-woo Jul 5, 2024 05:49am
- More options became available with the approval of biologics and JAK inhibitors to treat atopic dermatitis. However, limitations in switching treatments have been indicated to make effective treatments difficult. Opinions have been suggested that the Korean government must follow the global trend as foreign countries do not limit switching be
